Vildagliptin

CLINICAL USE

Treatment of type 2 diabetes mellitus in combination with other antidiabetic drugs

DOSE IN NORMAL RENAL FUNCTION

With metformin or thiazolidinedione: 50 mg twice daily With a sulphonylurea: 50 mg in the morning

PHARMACOKINETICS

Molecular weight : 303.4

%Protein binding : 9.3

%Excreted unchanged in urine : 23

Volume of distribution (L/kg) : 71 litres

half-life – normal/ESRD (hrs) : 3/Increased

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 : Avoid

10 to 20 : Avoid

<10 : Avoid

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD : Not dialysed. Avoid

HD : Not dialysed. Avoid

HDF/high flux : Not dialysed. Avoid

CAV/VVHD : Not dialysed. Avoid

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

None known

ADMINISTRATION

Reconstition

–

Route

Oral

Rate of Administration

–

Comments

–

OTHER INFORMATION

Use is contraindicated in renal impairment due to lack of data Cases of hepatic dysfunction have occasionally been reported The main metabolite (LAY 151) is removed by haemodialysis .

See how to identify renal failure stages according to GFR calculation

See how to diagnose irreversible renal disease

Home